Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
Completed · Phase 4
Conditions studied: Schizophrenia
In brief
The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
Key facts
- Study ID
- NCT00103571
- Run by
- Eli Lilly and Company
- People needed
- 600
- Starts
- 2004-07-01
- Expected to finish
- 2006-08-01
- Last updated by the study team
- 2007-11-06
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must have schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Patients must be agitated
- Patients must display psychotic symptoms
- Patients must be inpatients who are expected to stay in the hospital for at least 5 days
- Patients must be 18 to 55 years of age
You may not qualify if…
- Patients may not be hospitalized for greater than 72 hours prior to study start
- Patients may not have received more than one dose of olanzapine or aripiprazole within 72 hours prior to study start
- Patients may not be actively suicidal
- Patients may not be diagnosed with substance-induced psychosis or substance dependence
- Patients may not have acute, serious, or unstable medical conditions
Where it is running
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test — Saint Charles, Missouri, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test — Beachwood, Ohio, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test — Canton, Ohio, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test — Memphis, Tennessee, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test — Rio Piedras, Puerto Rico
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.